Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058838 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT00058838 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 854 participants.
The verdict
NCT00058838, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease
Interventions
- DRUG sumanirole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058838
The ClinicalTrials.gov registry entry for NCT00058838 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 854 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sumanirole is the first listed.
NCT00058838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058838 about?
NCT00058838 is a clinical study titled "Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease". The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease
What is the current status of trial NCT00058838?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2003-04. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00058838?
The interventions under investigation include: sumanirole (DRUG).
Who is sponsoring clinical trial NCT00058838?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.